Listed

Madrigal Pharmaceuticals, Inc.: Form 10-K/A for the period ended Dec 31, 2022

Filed with the SEC on Mar 3, 2023 and accepted by EDGAR at Mar 3, 2023, 16:17 ET.

Share

Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2022-10-01 to 2022-12-31−$85.3mus-gaap:OperatingIncomeLoss
Operating income12 months2022-01-01 to 2022-12-31−$293.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-10-01 to 2022-12-31$1.7mus-gaap:InterestExpense
Interest expense12 months2022-01-01 to 2022-12-31$4.0mus-gaap:InterestExpense
Income tax12 months2022-01-01 to 2022-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-10-01 to 2022-12-31−$85.9mus-gaap:NetIncomeLoss
Net income12 months2022-01-01 to 2022-12-31−$295.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-10-01 to 2022-12-31−$4.98us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2022-01-01 to 2022-12-31−$17.23us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-10-01 to 2022-12-31−$4.98us-gaap:EarningsPerShareBasic
Basic EPS12 months2022-01-01 to 2022-12-31−$17.23us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-10-01 to 2022-12-3117,237,517 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)12 months2022-01-01 to 2022-12-3117,137,201 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2022-01-01 to 2022-12-31−$224.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2022-01-01 to 2022-12-31$217.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-12-31$331.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-12-31$361.4mus-gaap:AssetsCurrent
Total assetsAt period end2022-12-31$362.6mus-gaap:Assets
Current liabilitiesAt period end2022-12-31$115.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-12-31$165.2mus-gaap:Liabilities
Long-term debtAt period end2022-12-31$49.3mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2022-12-31$197.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-23-060052. Last ingested by Listed: Nov 6, 2026, 18:49 ET. Listed shows no prices and gives no investment advice.